The In Vitro Fertilization - Lipiodol Uterine Bathing Effect Study
The in Vitro Fertilisation - Lipiodol Uterine Bathing Effect Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Neil Johnson, MD
- Phone Number: +64 274360172
- Email: n.johnson@auckland.ac.nz
Study Contact Backup
- Name: Shelley Reilly, MRANZCOG
- Email: sreilly@adhb.govt.nz
Study Locations
-
-
-
Auckland, New Zealand
- Recruiting
- University of Auckland
-
Contact:
- Neil Johnson, MD
- Phone Number: +64 274 360172
- Email: n.johnson@auckland.ac.nz
-
Principal Investigator:
- Neil P Johnson, MD
-
Sub-Investigator:
- Shelley J Reilly, MRANZCOG
-
Sub-Investigator:
- Cindy M Farquhar, MD
-
Sub-Investigator:
- Alistair Stewart
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 12 or more months infertility
- Age 18 to 39
- Endometriosis or recurrent IVF implantation failure
- Patent fallopian tubes
Exclusion Criteria:
- Iodine allergy
- Blocked fallopian tube or tubes
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Recurrent IVF implantation failure
|
IVF preceded by lipiodol
IVF alone
|
|
EXPERIMENTAL: Endometriosis
|
IVF preceded by lipiodol
IVF alone
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Live birth
Time Frame: 12 months post-randomization
|
12 months post-randomization
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Clinical pregnancy
Time Frame: 3 months post-randomization
|
3 months post-randomization
|
|
Adverse events
Time Frame: 3 & 12 months post-randomization
|
3 & 12 months post-randomization
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Neil Johnson, MD, University of Auckland, New Zealand
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IVF-LUBE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.